Time From HIV Infection to Diagnosis in the U.S., 2014-2018.

Anne H Peruski, Baohua Wu, Laurie Linley, Kevin P Delaney, Elizabeth A DiNenno, Anna Satcher Johnson
Author Information
  1. Anne H Peruski: Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: aperuski@cdc.gov.
  2. Baohua Wu: Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
  3. Laurie Linley: Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
  4. Kevin P Delaney: Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
  5. Elizabeth A DiNenno: Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
  6. Anna Satcher Johnson: Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.

Abstract

INTRODUCTION: Understanding the role of sociologic, structural, and biomedical factors that influence the length of time from HIV infection to diagnosis and reducing the time from infection to diagnosis are critical for achieving the goals of the Ending the HIV Epidemic initiative. In a retrospective analysis, the length of time from HIV infection to diagnosis and its association with individual- and facility-level attributes are determined.
METHODS: Data reported by December 2019 to the U.S. National HIV Surveillance System for people with HIV diagnosed during 2014-2018 were analyzed during December 2020. A CD4 depletion model was used to estimate the time from HIV infection to diagnosis.
RESULTS: During 2018, the median time from HIV infection to diagnosis was shorter for those infections diagnosed using the rapid testing algorithm (30.3 months, 95% CI=25.5, 34.5) than those diagnosed using the recommended (41.0 months, 95% CI=39.5, 42.0), traditional (37.0 months, 95% CI=29.5, 43.5), or other (35.5 months, 95% CI=32.5, 38.0) diagnostic testing algorithms. From 2014 to 2018, the time from HIV infection to diagnosis remained stable overall for all testing methods except for the traditional diagnostic testing algorithm. In multivariate analyses, those more likely to have HIV diagnosed closer to the time of infection were younger, were White, had transmission risk factors of injection drug use or heterosexual contact (for female individuals) or male-to-male sexual contact and injection drug use, or had HIV diagnosed at a correctional or screening facility (p<0.01).
CONCLUSIONS: Providing access to expanded testing, including rapid testing in nonclinical settings, is likely to result in a decrease in the length of time a person is unaware of their HIV infection and thus reduce onward transmission of HIV infection.

References

  1. AIDS. 2010 Nov 13;24(17):2697-704 [PMID: 20885283]
  2. Clin Infect Dis. 2013 Mar;56(6):888-97 [PMID: 23223594]
  3. J Infect Dis. 2020 Sep 2;222(Suppl 5):S239-S249 [PMID: 32877545]
  4. J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):3-9 [PMID: 27509244]
  5. Clin Infect Dis. 2020 Nov 5;71(8):e308-e315 [PMID: 31813966]
  6. Am J Public Health. 2019 Nov;109(11):1589-1595 [PMID: 31536400]
  7. Rev Saude Publica. 2016 Sep 01;50:55 [PMID: 27598785]
  8. J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):505-512 [PMID: 29697595]
  9. MMWR Morb Mortal Wkly Rep. 2019 Jun 28;68(25):561-567 [PMID: 31246940]
  10. Sex Transm Dis. 2018 Nov;45(11):707-712 [PMID: 29771868]
  11. Glob J Health Sci. 2015 Nov 03;8(7):9-17 [PMID: 26925893]
  12. J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):116-122 [PMID: 28700407]
  13. Public Health Rep. 2008 Sep-Oct;123(5):618-27 [PMID: 18828417]
  14. MMWR Morb Mortal Wkly Rep. 2017 Dec 01;66(47):1300-1306 [PMID: 29190267]
  15. Clin Infect Dis. 2017 Jan 1;64(1):53-59 [PMID: 27737954]
  16. J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):248-51 [PMID: 25714245]
  17. Public Health Rep. 2016 Jan-Feb;131 Suppl 1:1-4 [PMID: 26862224]
  18. Ann Emerg Med. 2011 Jul;58(1 Suppl 1):S126-32.e1-4 [PMID: 21684391]
  19. JAMA. 2019 Mar 5;321(9):844-845 [PMID: 30730529]
  20. J Am Pharm Assoc (2003). 2014 Sep-Oct;54(5):486-92 [PMID: 25216878]
  21. J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):78-86 [PMID: 26284530]
  22. J Clin Virol. 2012 May;54(1):42-7 [PMID: 22381919]
  23. Drug Alcohol Depend. 2016 Aug 01;165:270-4 [PMID: 27323649]
  24. MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17; quiz CE1-4 [PMID: 16988643]
  25. Clin Infect Dis. 2011 Oct;53(8):817-25 [PMID: 21921225]
  26. MMWR Suppl. 1989 Jul 21;38(7):1-7 [PMID: 2501638]
  27. J Natl Black Nurses Assoc. 2018 Dec;29(2):1-8 [PMID: 31022333]
  28. MMWR Morb Mortal Wkly Rep. 2018 Mar 22;68(11):267-272 [PMID: 30897075]
  29. Qual Health Res. 2016 Feb;26(3):294-306 [PMID: 26631679]

Grants

  1. CC999999/Intramural CDC HHS

MeSH Term

Female
HIV Infections
Humans
Male
Mass Screening
Retrospective Studies
Sexual Behavior
Substance Abuse, Intravenous

Word Cloud

Created with Highcharts 10.0.0HIVinfectiontime5diagnosistestingdiagnosedmonths95%0lengthfactorsDecemberUS2014-20182018usingrapidalgorithmtraditionaldiagnosticlikelytransmissioninjectiondrugusecontactINTRODUCTION:UnderstandingrolesociologicstructuralbiomedicalinfluencereducingcriticalachievinggoalsEndingEpidemicinitiativeretrospectiveanalysisassociationindividual-facility-levelattributesdeterminedMETHODS:Datareported2019NationalSurveillanceSystempeopleanalyzed2020CD4depletionmodelusedestimateRESULTS:medianshorterinfections303CI=2534recommended41CI=394237CI=294335CI=3238algorithms2014remainedstableoverallmethodsexceptmultivariateanalysescloseryoungerWhiteriskheterosexualfemaleindividualsmale-to-malesexualcorrectionalscreeningfacilityp<001CONCLUSIONS:ProvidingaccessexpandedincludingnonclinicalsettingsresultdecreasepersonunawarethusreduceonwardTimeInfectionDiagnosis

Similar Articles

Cited By